SpectrumAi, a Los Angeles-based behavioral health technology startup, announced Thursday that it has raised $20 million in Series A funding. The round was led by CVS Health Ventures, with participation from Cobalt Ventures and follow-on investments from seed investors F-Prime, Frist Cressey, and the Autism Impact Fund. This latest funding builds on the company’s $9 million seed round from June 2022 and comes just two years after SpectrumAi was founded in 2021. The Series A investment will accelerate the development of SpectrumAi’s innovative platforms: Twyll, an electronic health record (EHR) tailored for ABA therapy, and Patterns, a network analytics platform that aggregates and analyzes clinical data. Both tools are central to the company’s mission of modernizing ABA therapy technology by introducing objective measurement and robust data capture to a historically subjective field.
“ABA providers and their employees crave better data capture, documentation, and objective measurement of ABA therapy,” said Ling Shao, CEO and founder of SpectrumAi. “SpectrumAi provides front-line technicians and clinicians with powerful tools to help each child reach their optimal outcome using cutting-edge ABA therapy technology.”
Addressing Critical Gaps in ABA Therapy Technology
Applied behavior analysis is widely recognized as an effective intervention for autism spectrum disorder (ASD). However, the industry has long struggled with inconsistent data collection, subjective treatment assessments, and limited standardization. SpectrumAi’s ABA therapy technology aims to address these challenges by providing real-time session management, automated documentation, and data-driven insights that improve both clinical decision-making and treatment outcomes.
Twyll simplifies session management and automates the capture of behavioral data, while Patterns uses analytics to detect trends, identify opportunities for intervention, and provide actionable insights for payers and administrators. By combining these tools, SpectrumAi’s ABA therapy technology empowers providers to measure therapy effectiveness objectively, making the case for value-based care models.
“Data collection and documentation is fundamental to creating value-based contracting for the ABA industry,” said Vijay Patel, managing partner at CVS Health Ventures. “Our investment supports SpectrumAi’s disruptive ABA therapy technology and its potential to fill a significant data void in the industry.”
Driving the Shift to Value-Based Care
Traditionally, ABA therapy operates under fee-for-service reimbursement, which rewards session quantity rather than measurable outcomes. SpectrumAi’s ABA therapy technology helps providers transition to value-based care by delivering standardized, objective data that demonstrates patient progress and informs reimbursement decisions. This approach not only benefits payers and providers but also ensures children receive treatment tailored to their unique needs.
“ABA therapy has historically relied on subjective observations,” Shao noted. “Our technology allows clinicians to move beyond this model, using ABA therapy technology to track and measure real progress for each child.”
Investment Confidence Amid Market Turbulence
CVS Health Ventures has actively invested in behavioral health technology over the past year, including funding for telepsychiatry provider Array Behavioral Care, virtual care company Carbon Health, and virtual addiction treatment provider Workit Health. The ABA therapy technology developed by SpectrumAi attracted attention even amid market uncertainty caused by the collapses of Silicon Valley Bank, Signature Bank, and Silvergate Capital. These failures have shaken confidence in tech startups, yet SpectrumAi’s Series A shows strong investor belief in the company’s innovation and potential impact.
Targeting Providers and Payers for Maximum Impact
SpectrumAi primarily serves ABA therapy providers seeking to modernize operations and improve treatment tracking. The company also collaborates with payers, providing access to aggregate, actionable data to support value-based care adoption. By offering a combination of real-time analytics, documentation tools, and network insights, SpectrumAi’s ABA therapy technology is shaping the future of autism therapy and setting a new standard for measurable outcomes in behavioral health.
Founded in 2021, SpectrumAi has quickly become a leader in ABA therapy technology, helping providers and payers alike embrace data-driven, evidence-based care. With its $20 million Series A, the company is poised to expand its offerings, enhance analytics capabilities, and continue modernizing ABA therapy practices, ensuring that children receive the right care at the right intensity, backed by measurable outcomes.
